FT-4202, an allosteric activator of pyruvate kinase-R, demonstrates proof of mechanism and proof of concept after a single dose and after multiple daily doses in a phase 1 study of patients with sickle cell disease

Authors
Category Primary study
ConferenceBlood
Year 2020
This article has no abstract
Epistemonikos ID: ef602828b33eab92a9e3c2ad576463113bf3f86f
First added on: Feb 12, 2025